Literature DB >> 20012553

Copper(II) complexes of methimazole, an anti Grave's disease drug. Synthesis, characterization and its potential biological behavior as alkaline phosphatase inhibitor.

Nora M Urquiza1, Silvia G Manca, María A Moyano, Raquel Arrieta Dellmans, Luis Lezama, Teófilo Rojo, Luciana G Naso, Patricia A M Williams, Evelina G Ferrer.   

Abstract

Methimazole (MeimzH) is an anti-thyroid drug and the first choice for patients with Grave's disease. Two new copper(II) complexes of this drug: [Cu(MeimzH)(2)(NO(3))(2)]*0.5H(2)O and [Cu(MeimzH)(2)(H(2)O)(2)](NO(3))(2)*H(2)O were synthesized and characterized by elemental analysis, dissolution behavior, thermogravimetric analysis and UV-vis, diffuse reflectance, FTIR and EPR spectroscopies. As it is known that copper(II) cation can act as an inhibitor of alkaline phosphatase (ALP), the inhibitory effect of methimazole and its copper(II) complexes on ALP activity has also been investigated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20012553     DOI: 10.1007/s10534-009-9283-7

Source DB:  PubMed          Journal:  Biometals        ISSN: 0966-0844            Impact factor:   2.949


  1 in total

1.  Potential bio-protective effect of copper compounds: mimicking SOD and peroxidases enzymes and inhibiting acid phosphatase as a target for anti-osteoporotic chemotherapeutics.

Authors:  Nancy Martini; Juliana E Parente; Franco D Alessandro; Marilin Rey; Alberto Rizzi; Patricia A M Williams; Evelina G Ferrer
Journal:  Mol Biol Rep       Date:  2018-12-01       Impact factor: 2.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.